Global Utilization And Registry Database for Improved heArt preservatioN
Condition(s) studied
Investigational drug(s) / intervention(s)
SherpaPak Cardiac Transport System: The Paragonix SherpaPak Cardiac Transport System ("SherpaPak CTS") is an ultraportable hypothermic preservation and transport system intended for use with donor hearts. The device is a legally marketed, FDA cleared medical device in the United States and CE Marked medical device in the European Union. The SherpaPak CTS consists of multiple components: 1) outer transport shipper which contains within various non-ice based temperature controlled packaging elements, 2) an inner and outer hard shell assembly which provides a rigid barrier enclosure in which the heart is immersed and suspended in a cold storage solution cleared for use in storing and transporting donor hearts, 3) a data logger that monitors and displays the temperature of the cold storage solution in which the heart is stored during transport, and 4) four size heart connectors designed to accommodate various size aortic stem diameters by which donor hearts are attached.
Study summary
The primary objective of this study is to collect real-world clinical performance data to assess the clinical outcomes of patients receiving heart transplants using donor hearts transported via the SherpaPak CTS System. These results will be compared to outcomes of retrospective patients whose hearts were transported with the previous standard method.
CONCERT DCD is a substudy designed to assess the safety and feasibility of a direct procurement method for donation after circulatory death (DCD) heart procurement (CONCERT DCD) that utilizes preservation in a SherpaPak Cardiac Transport System. This DCD Substudy will be limited to approved GUARDIAN-Heart Registry sites who have been qualified to participate. The DCD Substudy will include prospective recipient identification and documentation of informed consent.
Eligibility
Primary outcome measure(s)
- Number of Patients with Primary Graft Dysfunction — one year
Less than 40% LVEF by echocardiography or hemodynamics with RAP greater than 15 mm Hg, PCWP greater than 20 mm Hg, CI less thann 2 L/min/m\^2, hypotension with MAP less than 70 mm Hg (lasting more than 1 hour) - Number of Patients with Right Ventricular Dysfunction — one year
hemodynamics with RAP grater than 15mm Hg, PCWP less than 15 mm Hg, CI less than 2 L/min/m\^2, TPG less than 15mm Hg/pulmonary artery systolic pressure less than 50 mmHg OR need for RVAD - Length of ICU Stay — one year
Length of time patient admitted to the intensive care unit post transplant - Length of Hospital Stay — one year
Length of time before patient is discharged from the hospital post transplant - Survival — 5 years
The length of patient survival up to 5 years will be compared
Trial sites (22)
| Facility | City | Region | Status |
|---|---|---|---|
| Stanford University | Stanford | California | |
| Medstar Washington Hospital | Washington D.C. | District of Columbia | |
| University of Florida Health Shands Hospital | Gainesville | Florida | |
| Mayo Clinic | Jacksonville | Florida | |
| AdventHealth Orlando | Orlando | Florida | |
| Lutheran Hospital | Fort Wayne | Indiana | |
| Kansas University Medical Center | Lawrence | Kansas | |
| Tufts University Medical Center | Boston | Massachusetts | |
| Massachusetts General Hospital | Boston | Massachusetts | |
| Spectrum Health | Grand Rapids | Michigan | |
| NewYork-Presbyterian Columbia University Irving Medical Center | New York | New York | |
| Duke University | Durham | North Carolina | |
| Cincinnati Children's Hospital | Cincinnati | Ohio | |
| Pennslyvania State University | State College | Pennsylvania | |
| Le Bonheur Children's Hospital | Memphis | Tennessee | |
| Baylor University Medical Center | Dallas | Texas | |
| Sentara Healthcare | Norfolk | Virginia | |
| University of Graz | Graz | Austria | |
| Allgemeines Krankenhaus Wien | Vienna | Austria | |
| Hospital Universitario 12 de Octubre | Madrid | Spain | |
| Hospital Clínico Universitario de Valladolid | Valladolid | Spain | |
| Manchester University | Manchester | United Kingdom |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04141605 on ClinicalTrials.gov ↗ ← All trials in Spain